106 related articles for article (PubMed ID: 7616442)
21. Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists.
Zahradníková A; Minarovic I; Zahradník I
J Pharmacol Exp Ther; 2007 Aug; 322(2):638-45. PubMed ID: 17475903
[TBL] [Abstract][Full Text] [Related]
22. Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino] ethyl]-6- fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with verapamil.
Hefti F; Clozel JP; Osterrieder W
Arzneimittelforschung; 1990 Apr; 40(4):417-21. PubMed ID: 2357242
[TBL] [Abstract][Full Text] [Related]
23. Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine.
Véniant M; Clozel JP; Hess P; Wolfgang R
J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S55-8. PubMed ID: 1725005
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular T-type calcium channels: physiological and pharmacological significance.
Triggle DJ
J Hypertens Suppl; 1997 Dec; 15(5):S9-15. PubMed ID: 9481611
[TBL] [Abstract][Full Text] [Related]
25. Mibefradil (Ro 40-5967) blocks multiple types of voltage-gated calcium channels in cultured rat spinal motoneurones.
Viana F; Van den Bosch L; Missiaen L; Vandenberghe W; Droogmans G; Nilius B; Robberecht W
Cell Calcium; 1997 Oct; 22(4):299-311. PubMed ID: 9481480
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of voltage-gated L-type calcium channels by labedipinedilol-A involves protein kinase C in rat cerebrovascular smooth muscle cells.
Wu BN; Chen ML; Dai ZK; Lin YL; Yeh JL; Wu JR; Chen IJ
Vascul Pharmacol; 2009; 51(2-3):65-71. PubMed ID: 19298869
[TBL] [Abstract][Full Text] [Related]
27. Open state block by fendiline of L-type Ca++ channels in ventricular myocytes from rat heart.
Nawrath H; Klein G; Rupp J; Wegener JW; Shainberg A
J Pharmacol Exp Ther; 1998 May; 285(2):546-52. PubMed ID: 9580596
[TBL] [Abstract][Full Text] [Related]
28. Characterization of mibefradil block of the human heart delayed rectifier hKv1.5.
Perchenet L; Clément-Chomienne O
J Pharmacol Exp Ther; 2000 Nov; 295(2):771-8. PubMed ID: 11046117
[TBL] [Abstract][Full Text] [Related]
29. Mibefradil (Ro 40-5967) inhibits several Ca2+ and K+ currents in human fusion-competent myoblasts.
Liu JH; Bijlenga P; Occhiodoro T; Fischer-Lougheed J; Bader CR; Bernheim L
Br J Pharmacol; 1999 Jan; 126(1):245-50. PubMed ID: 10051142
[TBL] [Abstract][Full Text] [Related]
30. Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations.
Caballero R; Gómez R; Núñez L; Moreno I; Tamargo J; Delpón E
Cardiovasc Res; 2004 Dec; 64(3):457-66. PubMed ID: 15537499
[TBL] [Abstract][Full Text] [Related]
31. Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2.
Dilmac N; Hilliard N; Hockerman GH
Mol Pharmacol; 2004 Nov; 66(5):1236-47. PubMed ID: 15286207
[TBL] [Abstract][Full Text] [Related]
32. Studies on maitotoxin-induced intracellular Ca(2+) elevation in chinese hamster ovary cells stably transfected with cDNAs encoding for L-type Ca(2+) channel subunits.
Cataldi M; Secondo A; D'Alessio A; Taglialatela M; Hofmann F; Klugbauer N; Di Renzo G; Annunziato L
J Pharmacol Exp Ther; 1999 Aug; 290(2):725-30. PubMed ID: 10411584
[TBL] [Abstract][Full Text] [Related]
33. Voltage-dependent calcium channels.
Lacinová L
Gen Physiol Biophys; 2005 Jun; 24 Suppl 1():1-78. PubMed ID: 16096350
[TBL] [Abstract][Full Text] [Related]
34. Distinctions in the molecular determinants of charged and neutral dihydropyridine block of L-type calcium channels.
Lacinová L; An RH; Xia J; Ito H; Klugbauer N; Triggle D; Hofmann F; Kass RS
J Pharmacol Exp Ther; 1999 Jun; 289(3):1472-9. PubMed ID: 10336541
[TBL] [Abstract][Full Text] [Related]
35. The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation.
Billman GE; Hamlin RL
J Pharmacol Exp Ther; 1996 Jun; 277(3):1517-26. PubMed ID: 8667218
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of the neuroprotectant lubeluzole on bovine and mouse chromaffin cell calcium channel subtypes.
Hernández-Guijo JM; Gandía L; de Pascual R; García AG
Br J Pharmacol; 1997 Sep; 122(2):275-85. PubMed ID: 9313936
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers.
Campiani G; Fiorini I; De Filippis MP; Ciani SM; Garofalo A; Nacci V; Giorgi G; Sega A; Botta M; Chiarini A; Budriesi R; Bruni G; Romeo MR; Manzoni C; Mennini T
J Med Chem; 1996 Jul; 39(15):2922-38. PubMed ID: 8709127
[TBL] [Abstract][Full Text] [Related]
38. Mibefradil inhibition of T-type calcium channels in cerebellar purkinje neurons.
McDonough SI; Bean BP
Mol Pharmacol; 1998 Dec; 54(6):1080-7. PubMed ID: 9855637
[TBL] [Abstract][Full Text] [Related]
39. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
Noll G; Lüscher TF
Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
[TBL] [Abstract][Full Text] [Related]
40. The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts.
Clozel JP; Véniant M; Osterrieder W
Cardiovasc Drugs Ther; 1990 Jun; 4(3):731-6. PubMed ID: 1963792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
